Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/in vivo studies

Pharmaceutical Development and Technology

Volumn 15, Issue 3, 2010, Pages 258-265

  Gungor, Sevgi ^a   Okyar, Alper ^a   Erturk Toker, Sidika ^a   Baktir, Gul ^a   Ozsoy, Yildiz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Microsphere; Nasal delivery; Ondansetron hydrochloride; PLA; PLGA; Spray drying

Indexed keywords

DICHLOROMETHANE; MICROSPHERE; ONDANSETRON; ORGANIC SOLVENT; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; EMULSION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SPRAY DRYING; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; MALE; MICROSPHERES; NASAL CAVITY; ONDANSETRON; RATS; RATS, WISTAR;

EID: 77952080855     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903148257     Document Type: Article

References (37)

1. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev 1998;29:39-49.
2. Cornaz AL, Buri P. Nasal mucosa as an absorption barrier. Eur J Pharm Biopharm 1994;40:261-270.
3. Ozsoy Y. Particulate carriers for nasal administration. In: Kumar MNVR, editor. Handbook of particulate drug delivery. Vol. 2, Chapter 8. CA: American Scientific Publisher; 2008:143-164.
4. Tafaghodi M, Tabassi SAS, Jaafari M-R, Zakavi SR, Momennejad M. Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm 2004;280:125-135.
5. Yildiz A, Okyar A, Baktir G, Araman A, Ozsoy Y. Nasal administration of heparin-loaded microspheres based on poly (lactic acid). Farmaco 2005;60:919-924.
6. Ignatius AA, Claes le E. In vitro biocompatibility of bioresorbable polymers: poly (L, DL-lactide) and poly (L-lactide-coglycolide). Biomaterials 1996;17:831-839.
7. Giunchedi P, Gavini E, Bonacucina G, Palmieri G. Tabletted polylactide microspheres prepared by a w/o emulsion-spray drying method. J Microencapsul 2000;17:711-720.
8. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. PLGA microspheres for ocular delivery of a peptide drug, vancomycin using emulsifcation/spray-drying as the preparation method: In vitro/in vivo studies. Eur J Pharm Biopharm 2004;57:207-212.
9. ®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001;76:239-254.
10. Baras B, Benoit MA, Gillard J. Parameters influencing the antigen release from spray-dried poly (DL-lactide) microparticles. Int J Pharm 2000;200:133-145.
11. Fu YJ, Shyu SS, su FH, Yu PC. Development of biodegradable copoly (D, L-lactic/glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method. Colloids and Surfaces B: Biointerfaces 2002;25:269-279.
12. Blanco-Prieto MJ, Besseghir K, Zerbe O, Andris D, Orsolini P, Heimgartner F, Merkle HP, Gander B. In vitro and in vivo evaluation of a somastotatin analogue released from PLGA microspheres. J Control Release 2000;67:19-28.
13. Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human erythropoietin (rhEPO) loaded poly (lactideco-glycolide) microspheres: Influence of the encapsulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm 1998;45:295-305.
14. Conte U, Conti B, Giunchedi P, Maggi L. Spray dried polylactide microsphere preparation: Influence of the technological parameters. Drug Dev Ind Pharm 1994;20:235-258.
15. Baber N, Palmer JL, Frazer NM, Pritchard JF. Clinical pharmacology of ondansetron in postoperative nausea and vomiting. Eur J Anaesthesiol 1992;6:11-18.
16. Scarantino CW, Ornitz RD, Hoffman LG, Anderson RF. Radiation induced emesis: Effects of ondansetron. Semin Oncol 1992;19:38-43.
17. Roila F, Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109.
18. Wilde MI, Markham A. Ondansetron. Drugs 1996;52:773-794.
19. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
20. Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Release 1998;55:67-77.
21. Tugcu-Demiröz F, Acartürk F, Takka S. Investigation of colonspecific dosage forms of ondansetron prepared with natural polymers. Pharmazie 2006;61:916-919.
22. Hsyu PH, Pritchard JF, Bozigian HP, Lloyd TL, Griffin RH, Shamburek R, Krishna G, Barr WH. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharmacol Res 1994;11:156-159.
23. Gwak HS, Oh IS, Chun IK. In vitro percutaneous absorption of ondansetron hydrochloride from pressure-sensitive adhesive matrices through hairless mouse skin. Arch Pharm Res 2003;26:44-48.
24. Gwak HS, Oh IS, Chun IK. Transdermal delivery of ondansetron hydrochloride: Effects of vehicles and penetration enhancers. Drug Dev Ind Pharm 2004;30:187-194.
25. Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: An alternative route of drug delivery. Cancer Chemother Pharmacol 2000;45:432-434.
26. Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm 2008;349:101-107.
27. Steele G. Preformulation as an aid to product design in early drug develeopment. In: Gibson M, editor. Pharmaceutical preformulation and formulation. Chapt. 6. Florida: Interpharm/CRS; 2004:175-237.
28. Giunchedi P, Conte U, Chetoni P, Saettone M F. Pectin microspheres as ophthalmic carriers for piroxicam: Evaluation in vitro and in vivo in albino rabbits. Eur J Pharm Sci 1999;9:1-7.
29. Gander B, Wehrli E, Alder R, Merkle HP. Quality improvement of spray-dried protein loaded D, L-PLA microspheres by appropriate polymer solvent selection. J Microencapsul 1995;12:83-97.
30. Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev 1998;29:147-155.
31. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998;15:270-275.
32. Dillen K, Van der voort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 2004;275:171-187.
33. Vila A, Sanchez A, Tobio M, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24.
34. Zolnik BS, Burgess DJ. Evaulation of in vivo/in vitro release of dexamethasone from PLGA microspheres. J Control Release 2008;127:137-145.
35. Kissel T, Brich Z, Bantle S, Lancranjam I, Nimmerfall F, Vit P. Parenteral depot-systems on the basis of biodegradable polyesters. J Control Release 1991;16:27-42.
36. Gao P, Xu H, Ding P, Gao Q, Sun J, Chen D. Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 2007;330:1-5.
37. Somers GI, Harris AJ, Bayliss MK, Houston JB. The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: A comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes. Xenobiotica 2007;37:832-854.